ClinicalTrials.gg
Status unknownNCT05339282Updated May 6, 2022

Effectiveness of Empirical Antibiotic Use in Mild to Moderate Acute Inflammatory Gallbladder Disease

An interventional study of Laparoscopic cholecystectomy in Cholecystitis, Acute, sponsored by Seoul St. Mary's Hospital. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by Seoul St. Mary's Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
370
Allocation
Non-randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 13 studies in Cholecystitis, Acute with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Cholecystitis, Acute · Korea, Republic of.

Planned enrollment
Largest of 12
370 · median 176
Started
2022
with 1 other
No phase
10 of 13
1 open now
Registered
11th of 13
by date
Lead sponsor
4 of 13
Seoul St. Mary's Hospital

Among the 13 studies in Cholecystitis, Acute with a site in Korea, Republic of, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 with no phase, and was the 11th registered.

Cholecystitis, Acute

140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.

Browse Cholecystitis, Acute studies →

Open to participants now

1 of the 13 studies in Cholecystitis, Acute with a site in Korea, Republic of is open now. Recruiting first, the newest first:

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 20 Cholecystitis, Acute studies recruiting now, 16 (80%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 0 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cholecystitis, Acute with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial is an exploratory clinical trial that evaluates the necessity and effectiveness of empirical antibiotic use in mild and moderate acute inflammatory gallbladder diseases that require surgery, and the incidence of postoperative infection-related complications is compared.

Read the detailed description

Cholecystectomy is the standard treatment for acute cholecystitis, accompanied by pain and fever due to acute inflammation in cholelithiasis patients. Empirical antibiotics are generally used to treat inflammation and prevent exacerbation before and after surgery. According to a previous study that confirmed the use of empirical antibiotics (JAMA. 2014;312(2):145-154. doi:10.1001/jama.2014.7586), the incidence of infectious complications was 15% in the group that used empirical antibiotics, and 15% of those who did not use empirical antibiotics The incidence of infectious complications in the group was 17%, confirming that there was no significant difference between the two groups. Based on these results, it was confirmed that the use of antibiotics after surgery was not clinically effective in reducing postoperative complications of infection.

However, there is a lack of objective research and evidence on the efficacy of empirical antibiotic use, and the use of antibiotics that have not been proven in practice may lead to the extension of hospital stay, waste of medical resources, and an increase in medical expenses. In addition, it can cause the occurrence of multidrug-resistant bacteria, which has been revived due to many problems recently, so caution is required in its use.

If the same anti-inflammatory effect and postoperative results can be obtained only through surgical treatment in mild and moderate acute inflammatory gallbladder disease, it is expected that the indiscriminate use of antibiotics will be reduced, and side effects thereof will be prevented. Therefore, this study intends to determine the effective and rational use of antibiotics through randomized clinical trials according to empirical antibiotics in laparoscopic surgery for patients with acute cholecystitis without evidence of systemic infection. In addition, a multicenter, double-blind, prospective, randomized, placebo-controlled clinical trial according to the use of empirical antibiotics has not been conducted in Korea so far, and thus clinical usefulness is expected to be great.

study population

  1. Inclusion criteria

    • 19 years old or older - less than 70 years old
    • Those with mild (grade I by Tokyo guidelines) and severe (Grade Ⅱ) acute cholecystitis among the acute cholecystitis patient group
    • Cholecystitis with adhesions with surrounding organs due to gallbladder wall thickness of 4 mm or more or gallbladder inflammation
    • Those who voluntarily sign the written consent form after hearing and understanding the explanation of this clinical trial
  2. Exclusion criteria

    • Those who are scheduled for elective gallbladder surgery (chronic cholecystitis, etc.)
    • Gallbladder disease that is not an inflammatory disease (GB cancer, GB polyp)
    • Pregnant or lactating women
    • A person who performs surgery at the same time due to other organ diseases
    • Those with immune suppression and bleeding tendency
    • Those who underwent percutaneous biliary drainage (PTGBD) before surgery
    • Those who require drainage tube installation during surgery
    • Those who are hypersensitive to cephalosproline antibiotics
    • Those who participated in other clinical trials within 3 months before screening
    • Other investigators who are judged inappropriate to participate in this clinical trial
  3. Target number of subjects and calculation basis Since this study was a comparison with a reference drug, the number of subjects was calculated using a non-inferiority test. To calculate the number of study subjects, in the existing literature, the incidence of surgical site infection was 15% in the group using antibiotics and 17% in the group not using antibiotics. The difference value of the ratio between the two groups was 2% larger in the test group than in the control group, and the study subjects were calculated assuming 11%, the upper limit of the confidence interval between the two groups, as the non-inferiority margin. As a result, 166 subjects in each group are required, 10%. If the dropout rate is calculated, 185 per group, a total of 370 subjects, is required.

Study design

  1. Design of clinical trials This clinical trial is an exploratory clinical trial evaluating the safety and effectiveness of using empirical antibiotics in mild and moderate acute inflammatory gallbladder disease requiring surgery. After determining whether the selection/exclusion criteria are suitable on the day of surgery, only suitable subjects are randomly assigned to the test group and control group in a 1:1 ratio. For the control group, the clinical investigational drug (Cefazolin 1g) was administered through an intravenous injection within 1 hour before the surgical site incision so that the concentration of antibiotics could be sufficiently maintained at the time of incision at the surgical site and the test group was administered with physiological saline without antibiotics do. Empirical antibiotics and saline are administered repeatedly at 24-hour intervals from the first dose until the patient is discharged.

    On the day of operation (OP day) and discharge, adverse reaction investigations, laboratory tests, and physical examinations for safety and efficacy evaluation are performed to evaluate the postoperative pain level and hospitalization period. One week after discharge, an outpatient visit is performed to evaluate adverse reactions, laboratory tests, and physical examinations to evaluate postoperative pain, the occurrence of postoperative infection-related complications, complications other than infection, and the need for additional procedures. In addition, when visiting the emergency room due to infection-related complications within a month after discharge, evaluate and compare the degree of postoperative pain, readmission, complications other than infection, and the need for additional procedures.

  2. Method of subject registration and randomization Subjects who have listened to the explanation of this clinical trial and agreed to voluntarily participate in the trial will be given a subject identification code in the order in which they signed the consent form at the screening visit. Randomization is performed to ensure the scientific validity of clinical trials by ensuring that the subjectivity of the investigator is not involved in the assignment.

Block randomization is performed to divide the patients into 2 groups and allocate them in a 1:1 ratio for patients who satisfy the selection/exclusion criteria and agree to participate in the clinical trial. For randomization, a statistician independent of this clinical trial generates a randomization number using SAS ver.9.4 for Microsoft Windows (SAS Institute Inc, NC, Cary, USA) or higher and assigns them sequentially.

Method of operation

  1. Surgery was started under general anesthesia
  2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.
  3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.

    • Double pressure through CO2 gas was maintained at 12mmHg / and 2L / min.
  4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.

    • The cystic duct was ligated with a 10mm clip, and the cystic artery was also ligated with a 10mm clip.
    • If the cystic duct was unstably ligated, ligation was performed through an end loop.
    • After ligation, the gallbladder was dissected from the liver.
  5. Washed the surgical site.
  6. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.
  7. The trocar was removed, the skin was sutured, and the operation was completed.

characteristics of observational and clinical test

  • Hematology tests: Hematocrit, Hemoglobin, Platelet, WBC \& Differential count
  • Blood coagulation test: PT INR, aPTT, BT
  • Blood chemistry test: SGOT (AST), SGPT (ALT), alkaline phosphatase, γ-GTP, bilirubin (total / direct), fasting plasma glucose, BUN, creatinine, sodium, potassium, chloride, total protein, albumin, uric acid, CPK, LDH, CRP
  • Imaging medical examination
  • Postoperative hospital stay
  • Check for infection.
  • Check for leakage of bile.
  • Surgery time and bleeding amount were described.
  • Postoperative complications

Statistical analysis In the case of categorical variables for the length of stay, surgical time, and complication data obtained as secondary endpoints, n (%) was presented, and the ratio difference between the two groups was tested using Chi-square or Fisher's exact test. In addition, for continuous variables, the mean, standard deviation, median, minimum, and maximum values were presented. The normality test was performed to test with Student's t-test for normal distribution and the non-normal distribution Wilcoxon rank-sum test. The difference between the two groups would be tested. All statistical analyses would use SPSS version 21.0, and it would be judged that it was statistically significant below the significance level of 0.05.

03

Conditions studied

  • Cholecystitis, Acute

Keywords

  • empirical antibiotics
  • postoperative complication
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
  2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
  3. Gallbladder with surrounding organs due to gallbladder inflammation
  4. Patients over 19 years of age, under 70 years of age

Exclusion criteria

Exclusion Criteria:

  1. patients with elective gallbladder surgery (chronic cholecystitis)
  2. gallbladder disease not inflammatory disease (GB cancer, GB polyp)
  3. pregnant women, patients under 18 years of age, over 70 years of age
  4. patients with simultaneous surgery due to other organ diseases
  5. patients; liver transplant patients, kidney transplant patients, acquired immunodeficiency syndrome patients
  6. patients with hemorrhagic tendency, or with hematologic diseases
  7. Patients who underwent percutaneous cholecystectomy (PTGBD)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
370 participants (estimated)

Study arms

  • Experimental
    The experimental group in acute cholecystitis

    inclusion criteria 1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II) 2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging 3. Gallbladder with surrounding organs due to gallbladder inflammation 4. Patients over 19 years of age normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery.

    Procedure: Laparoscopic cholecystectomy

  • Experimental
    The controled group in acute cholecystitis

    1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II) 2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging 3. Gallbladder with surrounding organs due to gallbladder inflammation 4. Patients over 19 years of age First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery.

    Procedure: Laparoscopic cholecystectomy

Interventions

  • ProcedureLaparoscopic cholecystectomy

    Method of operation 1. Surgery was started under general anesthesia 2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen. 3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity. 4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy. 5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus. 6. The trocar was removed, and the skin was sutured On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)

    Also known as: hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed

06

What researchers measure

Primary outcomes

  1. Number of Participants with Infectious Postoperative Complications

    Incidence of infectious postoperative complications in patients who underwent a laparoscopic cholecystectomy due to grade I Tokyo guidelines for acute cholecystitis or grade II Tokyo guidelines for acute cholecystitis except the evidence of gallbladder perforation, with the first-generation cephalosporin and normal saline.

    Time frame: 30 days

Secondary outcomes

  1. Duration of hospitalization

    The duration between the operation day and the day of discharge

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 days

07

Study locations

1 site
  • Department of HBP Surgery, Seoul St. Mary's hospital
    Seoul, Seocho-gu, Banopo-dong 137-701, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2022; primary completion for Apr 2023, 11 months later.

Of 42 non-industry interventional studies with no phase under Cholecystitis, Acute, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 11 months is below that.

Counting every sponsor, half of 45 studies reached it within 20 months; a quarter within 9 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2022
First posted
Apr 21, 2022
StartEst.
May 1, 2022
Primary completionEst.
Apr 30, 2023
CompletionEst.
Apr 30, 2024
Last update
May 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05339282
Lead sponsor
Seoul St. Mary's Hospital
Responsible party
Taeho Hong (Professor, Seoul St. Mary's Hospital) — Principal investigator
First posted
Apr 21, 2022
Start date
May 1, 2022 (estimated)
Primary completion
Apr 30, 2023 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
May 6, 2022

Study contacts

Tae ho Hong, MD. PhD
Contact
gshth@catholic.ac.kr
+82-10-5206-5266
Sung eun Park, MD
Contact
carin337@naver.com
+82-10-5775-9351
Sung eun Park, MD
study director · The Catholic University of Korea

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion